Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy
MV Sitkovsky - Current Opinion in Pharmacology, 2020 - Elsevier
Abstract The anti-hypoxia-A2-Adenosinergic immunotherapies of cancer emerged as the
only available now approach to enable the tumor rejection in those progressing cancer
patients that are refractory to all other current treatments. Several different classes of drugs
are offered to inhibit the Hypoxia-HIF-1alpha-mediated and extracellular adenosine-A2A
adenosine receptor-mediated immunosuppressive signaling in tumor microenvironment. It is
suggested that the most promising treatments must include the blockade of cAMP-elevating …
only available now approach to enable the tumor rejection in those progressing cancer
patients that are refractory to all other current treatments. Several different classes of drugs
are offered to inhibit the Hypoxia-HIF-1alpha-mediated and extracellular adenosine-A2A
adenosine receptor-mediated immunosuppressive signaling in tumor microenvironment. It is
suggested that the most promising treatments must include the blockade of cAMP-elevating …